Stockscreener 앱 받기
2.43
0.83%
0.02
시장 영업 전:
2.38
-0.05
-2.06%
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
FATE|Fate Therapeutics Inc|Price:2.425|Chg%:+0.015 - TradingKey
Fate Therapeutics Inc (FATE) Cash Flow - TradingKey
Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fate Therapeutics, Inc. Revenue Breakdown – NASDAQ:FATE - TradingView
Fate Therapeutics Inc (FATE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
FATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
BlackRock, Inc. Reduces Stake in Fate Therapeutics Inc - GuruFocus
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits
FDA approves clinical testing of CAR T-cell therapy for AAV, other conditions - ANCA Vasculitis News
Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $3.11 - Moomoo
Fate Therapeutics’ FT-839 gains IND clearance - BioWorld News
H.C. Wainwright reiterates Fate Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Fate Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Can Fate Therapeutics (NASDAQ:FATE) Boost Healthcare Stocks? - Kalkine Media
FT819 shows first clinical activity in systemic sclerosis - CRISPR Medicine News
Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey
Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - Moomoo
Sector Update: Healthcare - Moomoo
Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - marketscreener.com
Fate Therapeutics receives FDA clearance for FT839 IND - grafa.com
Fate Therapeutics gains after IND clearance (FATE:NASDAQ) - Seeking Alpha
Fate Therapeutics Receives FDA Clearance Of Investigational New Drug Application For FT839 Product Candidate - marketscreener.com
Fate Therapeutics Announces FDA Clearance of IND for FT839 Dual-CAR T Cell Therapy in Autoimmune Disease - Quiver Quantitative
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate - GlobeNewswire
Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade) - Seeking Alpha
Fate Therapeutics looks to its pipeline as investors weigh long-term prospects - ad-hoc-news.de
Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54 - simplywall.st
Fate Therapeutics Presents Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis At ISSCR 2026 Annual Meeting - marketscreener.com
Fate Therapeutics to present FT819 data at stem cell meeting - Investing.com
Fate Therapeutics to present FT819 data at stem cell meeting By Investing.com - Investing.com Nigeria
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting - The Manila Times
Fate Therapeutics Announces Preliminary FT819 Data in Systemic Sclerosis for ISSCR 2026 Presentation - Quiver Quantitative
Fate Therapeutics to show early FT819 data in systemic sclerosis - Stock Titan
Fate Therapeutics (FATE) Slides to $2.92 as Support Levels Come Into FocusVolume Gap - dars.gov.et
Fate Therapeutics focuses on cell-based immunotherapy and long-term growth prospects - Ad-hoc-news.de
Fate Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline AdvancesEstimate Accuracy - dars.gov.et
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - The Manila Times
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Fate Therapeutics(FATE) Stock Options Chain | Quotes & News - Moomoo
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000 Value Benchmark - marketscreener.com
Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade
Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History - Benzinga
F6T Forecast — Price Target — Prediction for 2027 - TradingView
Fate Therapeutics sets out next steps, biotech stock in focus after cash preservation move - Ad-hoc-news.de
Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T) - TradingView
Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T) - TradingView
Fate Therapeutics, Inc. Actuals & Estimates (NASDAQ:FATE) - TradingView
Enterprise value to revenue forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Fate Therapeutics, Inc. Actuals & Estimates (FWB:F6T) - TradingView
Price to earnings forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Price to book forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Enterprise value to EBITDA forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Price to sales forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
FATE Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE) - The Globe and Mail
1.97%
0.83%
자본화:
|
볼륨(24시간):